Make final clinical trial data available
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 15 Jan 2021
- Due
- 28 Mar 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“with final data available 6-8 weeks thereafter”
What we found
Evidence strength A What the grades mean
The company repeatedly stated in filings throughout 2021 that it expected final data 6-8 weeks after reporting topline results in April 2021, indicating the final data had not yet been made available.
-
A Mateon Therapeutics Inc. 10-Q filed 2021-05-24
“we reported positive topline results in April 2021 and we expect final data available 6-8 weeks thereafter.” ✓ confirmed on the page
-
A Mateon Therapeutics Inc. 10-Q filed 2021-08-20
“we reported positive topline results in April 2021 and we expect final data as soon as available.” ✓ confirmed on the page
Market reaction: the shares moved +2.3% against the S&P 500 over the three sessions around the disclosure (21 May 2021 to 26 May 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Make
- Deliverable
- final clinical trial data
- Where
- India
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: completion of the trial
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Mateon Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-OTLC-022125 · Corrections policy